Search

Your search keyword '"Bashey, Asad"' showing total 863 results
Start Over Author "Bashey, Asad" Search Limiters Available in Library Collection
863 results on '"Bashey, Asad"'

1. Haploidentical vs. sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia

Author

Wieduwilt, Matthew J, Metheny, Leland, Zhang, Mei-Jie, Wang, Hai-Lin, Estrada-Merly, Noel, Marks, David I, Al-Homsi, A Samar, Muffly, Lori, Chao, Nelson J, Rizzieri, David, Gale, Robert Peter, Gadalla, Shahinaz M, Cairo, Mitchell S, Mussetti, Alberto, Gore, Steven D, Bhatt, Vijaya Raj, Patel, Sagar S, Michelis, Fotios V, Inamoto, Yoshihiro, Badawy, Sherif M, Copelan, Edward, Palmisiano, Neil, Kharfan-Dabaja, Mohamed A, Lazarus, Hillard M, Ganguly, Siddhartha, Bredeson, Christopher N, Perez, Miguel Angel Diaz, Cassaday, Ryan, Savani, Bipin N, Ballen, Karen Kuhn, Martino, Rodrigo, Wirk, Baldeep, Bacher, Ulrike, Aljurf, Mahmoud, Bashey, Asad, Murthy, Hemant S, Yared, Jean A, Aldoss, Ibrahim, Farhadfar, Nosha, Liu, Hongtao, Abdel-Azim, Hisham, Waller, Edmund K, Solh, Melhem, Seftel, Matthew, van der Poel, Marjolein WM, Grunwald, Michael Richard, Liesveld, Jane L, Kamble, Rammurti T, McGuirk, Joseph P, Munker, Reinhold, Cahn, Jean-Yves, Lee, Jong Wook, Freytes, Cesar O, Krem, Maxwell, Winestone, Lena E, Gergis, Usama, Nathan, Sunita, Olsson, Richard F, Verdonck, Leo F, Sharma, Akshay, Ringden, Olle, Friend, Brian D, Cerny, Jan, Choe, Hannah K, Chhabra, Saurabh, Nishihori, Taiga, Seo, Sachiko, George, Biju, Baxter-Lowe, Lee Ann, Hildebrandt, Gerhard C, de Lima, Marcos, Litzow, Mark R, Kebriaei, Partow, Hourigan, Christopher S, Abid, Muhammad Bilal, Weisdorf, Daniel J, and Saber, Wael

Subjects
Rare Diseases, Cancer, Pediatric, Pediatric Cancer, Stem Cell Research - Nonembryonic - Human, Orphan Drug, Hematology, Stem Cell Research, Transplantation, Good Health and Well Being, Fetal Blood, Hematopoietic Stem Cell Transplantation, Humans, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Retrospective Studies, Siblings, Unrelated Donors
Abstract

The role of haploidentical hematopoietic cell transplantation (HCT) using posttransplant cyclophosphamide (PTCy) for acute lymphoblastic leukemia (ALL) is being defined. We performed a retrospective, multivariable analysis comparing outcomes of HCT approaches by donor for adults with ALL in remission. The primary objective was to compare overall survival (OS) among haploidentical HCTs using PTCy and HLA-matched sibling donor (MSD), 8/8 HLA-matched unrelated donor (MUD), 7 /8 HLA-MUD, or umbilical cord blood (UCB) HCT. Comparing haploidentical HCT to MSD HCT, we found that OS, leukemia-free survival (LFS), nonrelapse mortality (NRM), relapse, and acute graft-versus-host disease (aGVHD) were not different but chronic GVHD (cGVHD) was higher in MSD HCT. Compared with MUD HCT, OS, LFS, and relapse were not different, but MUD HCT had increased NRM (hazard ratio [HR], 1.42; P = .02), grade 3 to 4 aGVHD (HR, 1.59; P = .005), and cGVHD. Compared with 7/8 UD HCT, LFS and relapse were not different, but 7/8 UD HCT had worse OS (HR, 1.38; P = .01) and increased NRM (HR, 2.13; P ≤ .001), grade 3 to 4 aGVHD (HR, 1.86; P = .003), and cGVHD (HR, 1.72; P ≤ .001). Compared with UCB HCT, late OS, late LFS, relapse, and cGVHD were not different but UCB HCT had worse early OS (≤18 months; HR, 1.93; P < .001), worse early LFS (HR, 1.40; P = .007) and increased incidences of NRM (HR, 2.08; P < .001) and grade 3 to 4 aGVHD (HR, 1.97; P < .001). Haploidentical HCT using PTCy showed no difference in survival but less GVHD compared with traditional MSD and MUD HCT and is the preferred alternative donor HCT option for adults with ALL in complete remission.

Published
2022

2. Incidence and impact of community respiratory viral infections in post‐transplant cyclophosphamide‐based graft‐versus‐host disease prophylaxis and haploidentical stem cell transplantation

Author

Mulroney, Carolyn M, Abid, Muhammad Bilal, Bashey, Asad, Chemaly, Roy F, Ciurea, Stefan O, Chen, Min, Dandoy, Christopher E, Perez, Miguel A Diaz, Friend, Brian D, Fuchs, Ephraim, Ganguly, Siddhartha, Goldsmith, Scott R, Kanakry, Christopher G, Kim, Soyoung, Komanduri, Krishna V, Krem, Maxwell M, Lazarus, Hillard M, Ljungman, Per, Maziarz, Richard, Nishihori, Taiga, Patel, Sagar S, Perales, Miguel‐Angel, Romee, Rizwan, Singh, Anurag K, Wingard, John Reid, Yared, Jean, Riches, Marcie, and Taplitz, Randy

Subjects
Prevention, Transplantation, Lung, Stem Cell Research - Nonembryonic - Human, Stem Cell Research, Hematology, Rare Diseases, Organ Transplantation, Orphan Drug, Cancer, Infection, Good Health and Well Being, Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Community-Acquired Infections, Cyclophosphamide, Female, Graft vs Host Disease, HLA Antigens, Hematopoietic Stem Cell Transplantation, Humans, Immunosuppressive Agents, Incidence, Kaplan-Meier Estimate, Leukemia, Living Donors, Male, Middle Aged, Myelodysplastic Syndromes, Proportional Hazards Models, Respiratory Tract Infections, Retrospective Studies, Siblings, Transplantation, Haploidentical, Virus Diseases, Young Adult, Respiratory viral infection, Post Transplant Cyclophosphamide, Allogeneic transplant, Cardiorespiratory Medicine and Haematology, Immunology
Abstract

Community respiratory viral infections (CRVIs) are associated with pulmonary function impairment, alloimmune lung syndromes and inferior survival in human leucocyte antigen (HLA)-matched allogeneic haematopoietic stem cell transplant (HCT) recipients. Although the incidence of viral infections in HLA-haploidentical HCT recipients who receive post-transplant cyclophosphamide (PTCy)-based graft-versus-host disease (GVHD) prophylaxis is reportedly increased, there are insufficient data describing the incidence of CRVIs and the impact of donor source and PTCy on transplant outcomes. Analysing patients receiving their first HCT between 2012 and 2017 for acute myeloid leukaemia, acute lymphoblastic leukaemia and myelodysplastic syndromes, we describe comparative outcomes between matched sibling transplants receiving either calcineurin-based GVHD prophylaxis (SibCNI, N = 1605) or PTCy (SibCy, N = 403), and related haploidentical transplants receiving PTCy (HaploCy, N = 757). The incidence of CRVIs was higher for patients receiving PTCy, regardless of donor type. Patients in the HaploCy cohort who developed a CRVI by day +180 had both a higher risk of treatment-related mortality [hazard ratio (HR) 2⋅14, 99% confidence interval (CI) 1⋅13-4⋅07; P = 0⋅002] and inferior 2-year overall survival (HR 1⋅65, 99% CI 1⋅11-2⋅43; P = 0⋅001) compared to SibCNI with no CRVI. This finding justifies further research into long-term antiviral immune recovery, as well as development of preventive and treatment strategies to improve long-term outcomes in such patients.

Published
2021

5. A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis

Author

Tamari, Roni, McLornan, Donal P., Ahn, Kwang Woo, Estrada-Merly, Noel, Hernández-Boluda, Juan Carlos, Giralt, Sergio, Palmer, Jeanne, Gale, Robert Peter, DeFilipp, Zachariah, Marks, David I., van der Poel, Marjolein, Verdonck, Leo F., Battiwalla, Minoo, Diaz, Miguel Angel, Gupta, Vikas, Ali, Haris, Litzow, Mark Robert, Lazarus, Hillard M., Gergis, Usama, Bashey, Asad, Liesveld, Jane, Hashmi, Shahrukh, Pu, Jeffrey J., Beitinjaneh, Amer, Bredeson, Christopher, Rizzieri, David, Savani, Bipin N., Abid, Muhammad Bilal, Ganguly, Siddhartha, Agrawal, Vaibhav, Ulrike Bacher, Vera, Wirk, Baldeep, Jain, Tania, Cutler, Corey, Aljurf, Mahmoud, Kindwall-Keller, Tamila, Kharfan-Dabaja, Mohamed A., Hildebrandt, Gerhard C., Pawarode, Attaphol, Solh, Melhem M., Yared, Jean A., Grunwald, Michael R., Nathan, Sunita, Nishihori, Taiga, Seo, Sachiko, Scott, Bart L., Nakamura, Ryotaro, Oran, Betul, Czerw, Tomasz, Yakoub-Agha, Ibrahim, and Saber, Wael

Published
2023
Full Text
View/download PDF

7. Optimal Donor for African Americans with Hematologic Malignancy: HLA-Haploidentical Relative or Umbilical Cord Blood Transplant

Author

Solomon, Scott R, Martin, Andrew St, Zhang, Mei-Jie, Ballen, Karen, Bashey, Asad, Battiwalla, Minoo, Baxter-Lowe, Lee Ann, Brunstein, Claudio, Chhabra, Saurabh, Perez, Miguel Angel Diaz, Fuchs, Ephraim J, Ganguly, Siddhartha, Hardy, Nancy, Hematti, Peiman, McGuirk, Joseph, Peres, Edward, Ringden, Olle, Rizzieri, David, Romee, Rizwan, Solh, Melhem, Szwajcer, David, van der Poel, Marjolein, Waller, Edmund, William, Basem M, and Eapen, Mary

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Immunology, Stem Cell Research, Stem Cell Research - Nonembryonic - Human, Clinical Research, Transplantation, Hematology, Stem Cell Research - Umbilical Cord Blood/ Placenta - Human, Rare Diseases, Cancer, Regenerative Medicine, Stem Cell Research - Umbilical Cord Blood/ Placenta, Good Health and Well Being, Black or African American, Cord Blood Stem Cell Transplantation, Fetal Blood, Graft vs Host Disease, Hematologic Neoplasms, Hematopoietic Stem Cell Transplantation, Histocompatibility Testing, Humans, Alternative donor, African American, Caucasian, race, leukemia, transplant-related mortality, Clinical Sciences, Cardiovascular medicine and haematology
Abstract

Although hematopoietic cell transplantation from an HLA-matched unrelated donor is potentially curative for hematologic malignancies, survival is lower for African Americans compared with Caucasians. Because only approximately 20% of African Americans will have an HLA-matched unrelated donor, many of these patients undergo HLA-haploidentical relative or umbilical cord blood transplantation. In this study, we analyzed outcomes after HLA-haploidentical related donor (n = 249) and umbilical cord blood (n = 118) transplantations in African American patients with hematologic malignancy between 2008 and 2016. The predominant disease was acute myelogenous leukemia for recipients of both types of donor grafts. The incidences of grade II-IV and III-IV acute graft-versus-host disease were higher after umbilical cord blood transplantation compared with HLA-haploidentical relative transplantation (56% and 29%, respectively, versus 33% and 11%, respectively; P < .0001). The 2-year incidence of transplantation-related mortality adjusted for age and conditioning regimen intensity was higher after umbilical cord blood transplantation compared with HLA-haploidentical related donor transplantation (31% versus 18%; P = .008); however, there were no between-group differences in the 2-year adjusted incidence of relapse (30% versus 34%; P = .51), overall survival (54% versus 57%; P = .66), or disease-free survival (43% versus 47%; P = .46). Our findings show that the use of HLA-haploidentical and umbilical cord blood transplants expands the access to transplantation with comparable leukemia-free and overall survival for African Americans with hematologic malignancies.

Published
2020

8. Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide.

Author

Im, Annie, Rashidi, Armin, Wang, Tao, Hemmer, Michael, MacMillan, Margaret, Pidala, Joseph, Jagasia, Madan, Pavletic, Steven, Majhail, Navneet, Weisdorf, Daniel, Abdel-Azim, Hisham, Agrawal, Vaibhav, Al-Homsi, A, Aljurf, Mahmoud, Askar, Medhat, Auletta, Jeffery, Bashey, Asad, Beitinjaneh, Amer, Bhatt, Vijaya, Byrne, Michael, Cahn, Jean-Yves, Cairo, Mitchell, Castillo, Paul, Cerny, Jan, Chhabra, Saurabh, Choe, Hannah, Ciurea, Stefan, Daly, Andrew, Perez, Miguel, Farhadfar, Nosha, Gadalla, Shahinaz, Gale, Robert, Ganguly, Siddhartha, Gergis, Usama, Hanna, Rabi, Hematti, Peiman, Herzig, Roger, Hildebrandt, Gerhard, Lad, Deepesh, Lee, Catherine, Lehmann, Leslie, Lekakis, Lazaros, Kamble, Rammurti, Kharfan-Dabaja, Mohamed, Khandelwal, Pooja, Martino, Rodrigo, Murthy, Hemant, Nishihori, Taiga, OBrien, Tracey, Olsson, Richard, Patel, Sagar, Perales, Miguel-Angel, Prestidge, Tim, Qayed, Muna, Romee, Rizwan, Schoemans, Hélène, Seo, Sachiko, Sharma, Akshay, Solh, Melhem, Strair, Roger, Teshima, Takanori, Urbano-Ispizua, Alvaro, Van der Poel, Marjolein, Vij, Ravi, Wagner, John, William, Basem, Wirk, Baldeep, Yared, Jean, Spellman, Steve, Arora, Mukta, and Hamilton, Betty

Subjects
Adult, Cyclophosphamide, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Risk Factors, Transplantation Conditioning
Abstract

Post-transplant cyclophosphamide (PTCy) has significantly increased the successful use of haploidentical donors with a relatively low incidence of graft-versus-host disease (GVHD). Given its increasing use, we sought to determine risk factors for GVHD after haploidentical hematopoietic cell transplantation (haplo-HCT) using PTCy. Data from the Center for International Blood and Marrow Transplant Research on adult patients with acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, or chronic myeloid leukemia who underwent PTCy-based haplo-HCT (2013 to 2016) were analyzed and categorized into 4 groups based on myeloablative (MA) or reduced-intensity conditioning (RIC) and bone marrow (BM) or peripheral blood (PB) graft source. In total, 646 patients were identified (MA-BM = 79, MA-PB = 183, RIC-BM = 192, RIC-PB = 192). The incidence of grade 2 to 4 acute GVHD at 6 months was highest in MA-PB (44%), followed by RIC-PB (36%), MA-BM (36%), and RIC-BM (30%) (P = .002). The incidence of chronic GVHD at 1 year was 40%, 34%, 24%, and 20%, respectively (P < .001). In multivariable analysis, there was no impact of stem cell source or conditioning regimen on grade 2 to 4 acute GVHD; however, older donor age (30 to 49 versus

Published
2020

9. Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation

Author

Al Malki, Monzr M, Yang, Dongyun, Labopin, Myriam, Afanasyev, Boris, Angelucci, Emanuele, Bashey, Asad, Socié, Gérard, Karduss-Urueta, Amado, Helbig, Grzegorz, Bornhauser, Martin, Niittyvuopio, Riitta, Ganser, Arnold, Ciceri, Fabio, Brecht, Arne, Koc, Yener, Bejanyan, Nelli, Ferraro, Francesca, Kebriaei, Partow, Mokhtari, Sally, Ghobadi, Armin, Nakamura, Ryotaro, Forman, Stephen J, Champlin, Richard, Mohty, Mohamad, Ciurea, Stefan O, and Nagler, Arnon

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Transplantation, Hematology, Stem Cell Research, Clinical Research, Stem Cell Research - Nonembryonic - Human, Rare Diseases, Pediatric Research Initiative, Good Health and Well Being, Adult, Cyclophosphamide, Humans, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Retrospective Studies, Transplantation Conditioning, Unrelated Donors, Cardiovascular medicine and haematology
Abstract

We compared outcomes of 1461 adult patients with acute lymphoblastic leukemia (ALL) receiving hematopoietic cell transplantation (HCT) from a haploidentical (n = 487) or matched unrelated donor (MUD; n = 974) between January 2005 and June 2018. Graft-versus-host disease (GVHD) prophylaxis was posttransplant cyclophosphamide (PTCy), calcineurin inhibitor (CNI), and mycophenolate mofetil (MMF) for haploidentical, and CNI with MMF or methotrexate with/without antithymoglobulin for MUDs. Haploidentical recipients were matched (1:2 ratio) with MUD controls for sex, conditioning intensity, disease stage, Philadelphia-chromosome status, and cytogenetic risk. In the myeloablative setting, day +28 neutrophil recovery was similar between haploidentical (87%) and MUD (88%) (P = .11). Corresponding rates after reduced-intensity conditioning (RIC) were 84% and 88% (P = .47). The 3-month incidence of grade II-IV acute GVHD (aGVHD) and 3-year chronic GVHD (cGVHD) was similar after haploidentical compared with MUD: myeloablative conditioning, 33% vs 34% (P = .46) for aGVHD and 29% vs 31% for cGVHD (P = .58); RIC, 31% vs 30% (P = .06) for aGVHD and 24% vs 29% for cGVHD (P = .86). Among patients receiving myeloablative regimens, 3-year probabilities of overall survival were 44% and 51% with haploidentical and MUD (P = .56). Corresponding rates after RIC were 43% and 42% (P = .6). In this large multicenter case-matched retrospective analysis, despite the limitations of a registry-based study (ie, unavailability of key elements such as minimal residual disease testing), our analysis indicated that outcomes of patients with ALL undergoing HCT from a haploidentical donor were comparable with 8 of 8 MUD transplantations.

Published
2020

10. Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT

Author

Dholaria, Bhagirathbhai, Savani, Bipin N, Labopin, Myriam, Luznik, Leo, Ruggeri, Annalisa, Mielke, Stephan, Malki, Monzr M Al, Kongtim, Piyanuch, Fuchs, Ephraim, Huang, Xiao-Jun, Locatelli, Franco, Aversa, Franco, Castagna, Luca, Bacigalupo, Andrea, Martelli, Massimo, Blaise, Didier, Soussan, Patrick Ben, Arnault, Yolande, Handgretinger, Rupert, Roy, Denis-Claude, O’Donnell, Paul, Bashey, Asad, Solomon, Scott, Romee, Rizwan, Lewalle, Philippe, Gayoso, Jorge, Maschan, Michael, Lazarus, Hillard M, Ballen, Karen, Giebel, Sebastian, Baron, Frederic, Ciceri, Fabio, Esteve, Jordi, Gorin, Norbert-Claude, Spyridonidis, Alexandros, Schmid, Christoph, Ciurea, Stefan O, Nagler, Arnon, and Mohty, Mohamad

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Immunology, Transplantation, Cancer, Regenerative Medicine, Rare Diseases, Prevention, Hematology, Stem Cell Research, Inflammatory and immune system, Consensus, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Lymphocytes, Prospective Studies, Retrospective Studies, Cardiorespiratory Medicine and Haematology, Cardiovascular medicine and haematology
Abstract

Donor lymphocyte infusion has been used in the management of relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. It can eradicate minimal residual disease or be used to rescue a hematologic relapse, being able to induce durable remissions in a subset of patients. With the increased use of haploidentical hematopoietic cell transplantation, there is renewed interest in the use of donor lymphocytes to either treat or prevent disease relapse post transplant. Published retrospective and small prospective studies have shown encouraging results with therapeutic donor lymphocyte infusion in different haploidentical transplantation platforms. In this consensus paper, finalized on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation, we summarize the available evidence on the use of donor lymphocyte infusion from haploidentical donor, and provide recommendations on its therapeutic, pre-emptive and prophylactic use in clinical practice.

Published
2020

11. Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy.

Author

Solomon, Scott, St Martin, Andrew, Shah, Nirav, Fatobene, Giancarlo, Al Malki, Monzr, Ballen, Karen, Bashey, Asad, Bejanyan, Nelli, Bolaños Meade, Javier, Brunstein, Claudio, DeFilipp, Zachariah, Champlin, Richard, Fuchs, Ephraim, Hamadani, Mehdi, Hematti, Peiman, Kanakry, Christopher, McGuirk, Joseph, McNiece, Ian, Ciurea, Stefan, Pasquini, Marcelo, Rocha, Vanderson, Romee, Rizwan, Patel, Sagar, Vasu, Sumithira, Waller, Edmund, Wingard, John, Zhang, Mei-Jie, and Eapen, Mary

Subjects
Adolescent, Adult, Disease-Free Survival, Female, Hematologic Neoplasms, Humans, Middle Aged, Myeloablative Agonists, Transplantation Conditioning, Transplantation, Haploidentical, Young Adult
Abstract

In the absence of prospective studies that examine the effect of conditioning regimen intensity after T-cell-replete haploidentical transplant for acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndrome (MDS), a retrospective cohort analysis was performed. Of the 1325 eligible patients (AML, n = 818; ALL, n = 286; and MDS, n = 221), 526 patients received a myeloablative regimen and 799 received a reduced-intensity regimen. Graft-versus-host disease prophylaxis was uniform with posttransplant cyclophosphamide, a calcineurin inhibitor, and mycophenolate mofetil. The primary end point was disease-free survival. Cox regression models were built to study the effect of conditioning regimen intensity on transplant outcomes. For patients aged 18 to 54 years, disease-free survival was lower (hazard ratio [HR], 1.34; 42% vs 51%; P = .007) and relapse was higher (HR, 1.51; 44% vs 33%; P = .001) with a reduced-intensity regimen compared with a myeloablative regimen. Nonrelapse mortality did not differ according to regimen intensity. For patients aged 55 to 70 years, disease-free survival (HR, 0.97; 37% vs 43%; P = .83) and relapse (HR, 1.32; 42% vs 31%; P = .11) did not differ according to regimen intensity. Nonrelapse mortality was lower with reduced-intensity regimens (HR, 0.64; 20% vs 31%; P = .02). Myeloablative regimens are preferred for AML, ALL, and MDS; reduced-intensity regimens should be reserved for those unable to tolerate myeloablation.

Published
2019

12. Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission.

Author

Rashidi, Armin, Hamadani, Mehdi, Zhang, Mei-Jie, Wang, Hai-Lin, Abdel-Azim, Hisham, Aljurf, Mahmoud, Assal, Amer, Bajel, Ashish, Bashey, Asad, Battiwalla, Minoo, Beitinjaneh, Amer, Bejanyan, Nelli, Bhatt, Vijaya, Bolaños-Meade, Javier, Byrne, Michael, Cahn, Jean-Yves, Cairo, Mitchell, Ciurea, Stefan, Copelan, Edward, Cutler, Corey, Daly, Andrew, Diaz, Miguel-Angel, Farhadfar, Nosha, Gale, Robert, Ganguly, Siddhartha, Grunwald, Michael, Hahn, Theresa, Hashmi, Shahrukh, Hildebrandt, Gerhard, Holland, H, Hossain, Nasheed, Kanakry, Christopher, Kharfan-Dabaja, Mohamed, Khera, Nandita, Koc, Yener, Lazarus, Hillard, Lee, Jong-Wook, Maertens, Johan, Martino, Rodrigo, McGuirk, Joseph, Munker, Reinhold, Murthy, Hemant, Nakamura, Ryotaro, Nathan, Sunita, Nishihori, Taiga, Palmisiano, Neil, Patel, Sagar, Pidala, Joseph, Olin, Rebecca, Olsson, Richard, Oran, Betul, Ringden, Olov, Rizzieri, David, Rowe, Jacob, Savoie, Mary, Schultz, Kirk, Seo, Sachiko, Shaffer, Brian, Singh, Anurag, Solh, Melhem, Stockerl-Goldstein, Keith, Verdonck, Leo, Wagner, John, Waller, Edmund, De Lima, Marcos, Sandmaier, Brenda, Litzow, Mark, Weisdorf, Dan, Romee, Rizwan, and Saber, Wael

Subjects
Adolescent, Adult, Aged, Blood Donors, Bone Marrow Transplantation, Calcineurin Inhibitors, Chronic Disease, Cyclophosphamide, Disease-Free Survival, Female, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Immunosuppressive Agents, Incidence, Leukemia, Myeloid, Acute, Male, Middle Aged, Recurrence, Remission Induction, Retrospective Studies, Siblings, Survival Analysis, Transplantation Conditioning, Transplantation, Haploidentical, Young Adult
Abstract

HLA-haploidentical hematopoietic cell transplantation (Haplo-HCT) using posttransplantation cyclophosphamide (PT-Cy) has improved donor availability. However, a matched sibling donor (MSD) is still considered the optimal donor. Using the Center for International Blood and Marrow Transplant Research database, we compared outcomes after Haplo-HCT vs MSD in patients with acute myeloid leukemia (AML) in first complete remission (CR1). Data from 1205 adult CR1 AML patients (2008-2015) were analyzed. A total of 336 patients underwent PT-Cy-based Haplo-HCT and 869 underwent MSD using calcineurin inhibitor-based graft-versus-host disease (GVHD) prophylaxis. The Haplo-HCT group included more reduced-intensity conditioning (65% vs 30%) and bone marrow grafts (62% vs 7%), consistent with current practice. In multivariable analysis, Haplo-HCT and MSD groups were not different with regard to overall survival (P = .15), leukemia-free survival (P = .50), nonrelapse mortality (P = .16), relapse (P = .90), or grade II-IV acute GVHD (P = .98). However, the Haplo-HCT group had a significantly lower rate of chronic GVHD (hazard ratio, 0.38; 95% confidence interval, 0.30-0.48; P < .001). Results of subgroup analyses by conditioning intensity and graft source suggested that the reduced incidence of chronic GVHD in Haplo-HCT is not limited to a specific graft source or conditioning intensity. Center effect and minimal residual disease-donor type interaction were not predictors of outcome. Our results indicate a lower rate of chronic GVHD after PT-Cy-based Haplo-HCT vs MSD using calcineurin inhibitor-based GVHD prophylaxis, but similar other outcomes, in patients with AML in CR1. Haplo-HCT is a viable alternative to MSD in these patients.

Published
2019

13. Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial

Author

Stadtmauer, Edward A, Pasquini, Marcelo C, Blackwell, Beth, Hari, Parameswaran, Bashey, Asad, Devine, Steven, Efebera, Yvonne, Ganguly, Siddharta, Gasparetto, Cristina, Geller, Nancy, Horowitz, Mary M, Koreth, John, Knust, Kristin, Landau, Heather, Brunstein, Claudio, McCarthy, Philip, Nelson, Courtney, Qazilbash, Muzaffar H, Shah, Nina, Vesole, David H, Vij, Ravi, Vogl, Dan T, Giralt, Sergio, Somlo, George, and Krishnan, Amrita

Subjects
Cancer, Clinical Trials and Supportive Activities, Hematology, Clinical Research, Rare Diseases, Transplantation, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Good Health and Well Being, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Bortezomib, Consolidation Chemotherapy, Dexamethasone, Disease Progression, Female, Hematopoietic Stem Cell Transplantation, Humans, Lenalidomide, Maintenance Chemotherapy, Male, Melphalan, Middle Aged, Multiple Myeloma, Myeloablative Agonists, Progression-Free Survival, Prospective Studies, Remission Induction, Reoperation, Time Factors, Transplantation, Autologous, United States, Young Adult, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeSingle-cycle melphalan 200 mg/m2 and autologous hematopoietic cell transplantation (AHCT) followed by lenalidomide (len) maintenance have improved progression-free survival (PFS) and overall survival (OS) for transplantation-eligible patients with multiple myeloma (MM). We designed a prospective, randomized, phase III study to test additional interventions to improve PFS by comparing AHCT, tandem AHCT (AHCT/AHCT), and AHCT and four subsequent cycles of len, bortezomib, and dexamethasone (RVD; AHCT + RVD), all followed by len until disease progression.Patients and methodsPatients with symptomatic MM within 12 months from starting therapy and without progression who were age 70 years or younger were randomly assigned to AHCT/AHCT + len (n = 247), AHCT + RVD + len (n = 254), or AHCT + len (n = 257). The primary end point was 38-month PFS.ResultsThe study population had a median age of 56 years (range, 20 to 70 years); 24% of patients had high-risk MM, 73% had a triple-drug regimen as initial therapy, and 18% were in complete response at enrollment. The 38-month PFS rate was 58.5% (95% CI, 51.7% to 64.6%) for AHCT/AHCT + len, 57.8% (95% CI, 51.4% to 63.7%) for AHCT + RVD + len, and 53.9% (95% CI, 47.4% to 60%) for AHCT + len. For AHCT/AHCT + len, AHCT + RVD + len, and AHCT + len, the OS rates were 81.8% (95% CI, 76.2% to 86.2%), 85.4% (95% CI, 80.4% to 89.3%), and 83.7% (95% CI, 78.4% to 87.8%), respectively, and the complete response rates at 1 year were 50.5% (n = 192), 58.4% (n = 209), and 47.1% (n = 208), respectively. Toxicity profiles and development of second primary malignancies were similar across treatment arms.ConclusionSecond AHCT or RVD consolidation as post-AHCT interventions for the up-front treatment of transplantation-eligible patients with MM did not improve PFS or OS. Single AHCT and len should remain as the standard approach for this population.

Published
2019

14. HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide

Author

Fuchs, Ephraim J., McCurdy, Shannon R., Solomon, Scott R., Wang, Tao, Herr, Megan R., Modi, Dipenkumar, Grunwald, Michael R., Nishihori, Taiga, Kuxhausen, Michelle, Fingerson, Stephanie, McKallor, Caroline, Bashey, Asad, Kasamon, Yvette L., Bolon, Yung-Tsi, Saad, Ayman, McGuirk, Joseph, Paczesny, Sophie, Gadalla, Shahinaz M., Marsh, Steven G.E., Shaw, Bronwen E., Spellman, Stephen R., Lee, Stephanie J., and Petersdorf, Effie W.

Published
2022
Full Text
View/download PDF

15. Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch?

Author

Robinson, Tara, Fuchs, Ephraim, Zhang, Mei-Jie, St Martin, Andrew, Labopin, Myriam, Keesler, Daniel, Blaise, Didier, Bashey, Asad, Bourhis, Jean-Henri, Ciceri, Fabio, Ciurea, Stefan, Devine, Steven, Mohty, Mohamad, McCurdy, Shannon, Milpied, Noel, McNiece, Ian, Rocha, Vanderson, Romee, Rizwan, Socie, Gerard, Yakoub-Agha, Ibrahim, Soiffer, Robert, Eapen, Mary, and Nagler, Arnon

Subjects
Acute Disease, Adolescent, Adult, Aged, Chronic Disease, Cyclophosphamide, Disease-Free Survival, Female, Graft vs Host Disease, HLA Antigens, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Male, Middle Aged, Survival Rate, Tissue Donors
Abstract

We sought to identify whether posttransplantation cyclophosphamide (PT-Cy) reduces or eliminates the detrimental impact of HLA mismatching on outcomes of HLA-haploidentical related donor transplantation for acute leukemia. Data from 2143 donor-recipient pairs (n = 218 haploidentical sibling; n = 218 offspring; n = 1707 HLA-matched sibling) with acute myeloid or lymphoblastic leukemia were studied. All received a calcineurin inhibitor for graft-versus-host disease (GVHD) prophylaxis while high-dose PT-Cy was also given to recipients of haploidentical transplant. Patient age correlated with donor-recipient relationship: haploidentical siblings donated to patients aged 18 to 54 years whereas offspring donated to patients aged 55 to 76 years. Therefore, transplant outcomes were examined separately in the 2 patient age groups. In patients aged 18 to 54 years, there were no significant differences in outcomes except chronic GVHD, which was lower after haploidentical sibling compared to HLA-matched sibling transplant (hazard ratio [HR], 0.63; P < .001). In patients aged 55 to 76 years, despite lower chronic GVHD (HR, 0.42; P < .001), graft failure (14% vs 6%; P = .003), nonrelapse mortality (HR, 1.48; P = .02), and overall mortality (HR, 1.32; P = .003) were higher after transplant from offspring compared with an HLA-matched sibling. These data demonstrate a superior outcome in older recipients when using an HLA-matched sibling instead of offspring, although there were differences in transplant platforms (GVHD prophylaxis and graft type) between the 2 groups. Validation of these findings requires a prospective randomized trial wherein the transplant platforms can be closely matched.

Published
2018

16. The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation

Author

Ciurea, Stefan O, Cao, Kai, Fernandez-Vina, Marcelo, Kongtim, Piyanuch, Malki, Monzr Al, Fuchs, Ephraim, Luznik, Leo, Huang, Xiao-Jun, Ciceri, Fabio, Locatelli, Franco, Aversa, Franco, Castagna, Luca, Bacigalupo, Andrea, Martelli, Massimo, Blaise, Didier, Handgretinger, Rupert, Roy, Denis-Claude, O’Donnell, Paul, Bashey, Asad, Lazarus, Hillard M, Ballen, Karen, Savani, Bipin N, Mohty, Mohamad, and Nagler, Arnon

Subjects
Transplantation, Regenerative Medicine, Stem Cell Research, Organ Transplantation, Development of treatments and therapeutic interventions, 5.4 Surgery, Inflammatory and immune system, Bone Marrow Transplantation, Graft Rejection, HLA Antigens, Hematopoietic Stem Cell Transplantation, Humans, Isoantibodies, Tissue Donors, Transplantation, Haploidentical, Treatment Outcome, Clinical Sciences, Oncology and Carcinogenesis, Immunology
Abstract

Haploidentical donors are now increasingly considered for transplantation in the absence of HLA-matched donors or when an urgent transplant is needed. Donor-specific anti-HLA antibodies (DSA) have been recently recognized as an important barrier against successful engraftment of donor cells, which can affect transplant survival. DSA appear more prevalent in this type of transplant due to higher likelihood of alloimmunization of multiparous females against offspring's HLA antigens, and the degree of mismatch. Here we summarize the evidence for the role of DSA in the development of primary graft failure in haploidentical transplantation and provide consensus recommendations from the European Society for Blood and Marrow Transplant Group on testing, monitoring, and treatment of patients with DSA receiving haploidentical hematopoietic progenitor cell transplantation.

Published
2018

17. Impact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantation

Author

Farhadfar, Nosha, Dias, Ajoy, Wang, Tao, Fretham, Caitrin, Chhabra, Saurabh, Murthy, Hemant S., Broglie, Larisa, D'Souza, Anita, Gadalla, Shahinaz M., Gale, Robert Peter, Hashmi, Shahrukh, Al-Homsi, A. Samer, Hildebrandt, Gerhard C., Hematti, Peiman, Rizzieri, David, Chee, Lynette, Lazarus, Hillard M., Bredeson, Christopher, Jaimes, Edgar A., Beitinjaneh, Amer, Bashey, Asad, Prestidge, Tim, Krem, Maxwell M., Marks, David I., Benoit, Stefanie, Yared, Jean A., Nishihori, Taiga, Olsson, Richard F., Freytes, Cesar O., Stadtmauer, Edward, Savani, Bipin N., Sorror, Mohamed L., Ganguly, Siddhartha, Wingard, John R., and Pasquini, Marcelo

Published
2021
Full Text
View/download PDF

18. Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors

Author

Grunwald, Michael R., Zhang, Mei-Jie, Elmariah, Hany, Johnson, Mariam H., St. Martin, Andrew, Bashey, Asad, Battiwalla, Minoo, Bredeson, Christopher N., Copelan, Edward, Cutler, Corey S., George, Biju R., Gupta, Vikas, Kanakry, Christopher, Mehta, Rohtesh S., Milano, Filippo, Mussetti, Alberto, Nakamura, Ryotaro, Nishihori, Taiga, Saber, Wael, Solh, Melhem, Weisdorf, Daniel J., and Eapen, Mary

Published
2021
Full Text
View/download PDF

19. Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for High-Risk Acute Lymphoblastic Leukemia.

Author

Srour, Samer, Milton, Denái, Bashey, Asad, Karduss-Urueta, Amado, Al Malki, Monzr, Romee, Rizwan, Solomon, Scott, Nademanee, Auayporn, Brown, Stacey, Slade, Michael, Perez, Rosendo, Rondon, Gabriela, Forman, Stephan, Champlin, Richard, Kebriaei, Partow, and Ciurea, Stefan

Subjects
Acute lymphoblastic leukemia, Haploidentical transplantation, Adolescent, Adult, Allografts, Cyclophosphamide, Disease-Free Survival, Drug Evaluation, Female, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Histocompatibility, Humans, Immunosuppressive Agents, Kaplan-Meier Estimate, Male, Middle Aged, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Retrospective Studies, Risk, Transplantation Conditioning, Young Adult
Abstract

Haploidentical transplantation performed with post-transplantation cyclophosphamide (PTCy)-based graft-versus-host disease (GVHD) prophylaxis has been associated with favorable outcomes for patients with acute myeloid leukemia and lymphomas. However, it remains unclear if such approach is effective for patients with acute lymphoblastic leukemia (ALL). We analyzed outcomes of 109 consecutively treated ALL patients 18 years of age and older at 5 institutions. The median age was 32 years and the median follow-up for survivors was 13 months. Thirty-two patients were in first complete remission (CR1), while the rest were beyond CR1. Neutrophil engraftment occurred in 95% of the patients. The cumulative incidences of grades II to IV and III and IV acute GVHD at day 100 after transplantation were 32% and 11%, respectively, whereas chronic GVHD, nonrelapse mortality, relapse rate, and disease-free survival (DFS) at 1 year after transplantation were 32%, 21%, 27%, and 51%, respectively. Patients in CR1 had 52% DFS at 3 years. These results suggest that haploidentical transplants performed with PTCy-based GVHD prophylaxis provide a very suitable alternative to HLA-matched transplantations for patients with ALL.

Published
2017

20. A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes

Author

Nazha, Aziz, Hu, Zhen-Huan, Wang, Tao, Lindsley, R. Coleman, Abdel-Azim, Hisham, Aljurf, Mahmoud, Bacher, Ulrike, Bashey, Asad, Cahn, Jean-Yves, Cerny, Jan, Copelan, Edward, DeFilipp, Zachariah, Diaz, Miguel Angel, Farhadfar, Nosha, Gadalla, Shahinaz M., Gale, Robert Peter, George, Biju, Gergis, Usama, Grunwald, Michael R., Hamilton, Betty, Hashmi, Shahrukh, Hildebrandt, Gerhard C., Inamoto, Yoshihiro, Kalaycio, Matt, Kamble, Rammurti T., Kharfan-Dabaja, Mohamed A., Lazarus, Hillard M., Liesveld, Jane L., Litzow, Mark R., Majhail, Navneet S., Murthy, Hemant S., Nathan, Sunita, Nishihori, Taiga, Pawarode, Attaphol, Rizzieri, David, Sabloff, Mitchell, Savani, Bipin N., Schachter, Levanto, Schouten, Harry C., Seo, Sachiko, Shah, Nirav N., Solh, Melhem, Valcárcel, David, Vij, Ravi, Warlick, Erica, Wirk, Baldeep, Wood, William A., Yared, Jean A., Alyea, Edwin, Popat, Uday, Sobecks, Ronald M., Scott, Bart L., Nakamura, Ryotaro, and Saber, Wael

Published
2020
Full Text
View/download PDF

24. Optimal Donor for African Americans with Hematologic Malignancy: HLA-Haploidentical Relative or Umbilical Cord Blood Transplant

Author

Solomon, Scott R., Martin, Andrew St, Zhang, Mei-Jie, Ballen, Karen, Bashey, Asad, Battiwalla, Minoo, Baxter-Lowe, Lee Ann, Brunstein, Claudio, Chhabra, Saurabh, Perez, Miguel Angel Diaz, Fuchs, Ephraim J., Ganguly, Siddhartha, Hardy, Nancy, Hematti, Peiman, McGuirk, Joseph, Peres, Edward, Ringden, Olle, Rizzieri, David, Romee, Rizwan, Solh, Melhem, Szwajcer, David, van der Poel, Marjolein, Waller, Edmund, William, Basem M., and Eapen, Mary

Published
2020
Full Text
View/download PDF

26. Survival following allogeneic transplant in patients with myelofibrosis

Author

Gowin, Krisstina, Ballen, Karen, Ahn, Kwang Woo, Hu, Zhen-Huan, Ali, Haris, Arcasoy, Murat O., Devlin, Rebecca, Coakley, Maria, Gerds, Aaron T., Green, Michael, Gupta, Vikas, Hobbs, Gabriela, Jain, Tania, Kandarpa, Malathi, Komrokji, Rami, Kuykendall, Andrew T., Luber, Kierstin, Masarova, Lucia, Michaelis, Laura C., Patches, Sarah, Pariser, Ashley C., Rampal, Raajit, Stein, Brady, Talpaz, Moshe, Verstovsek, Srdan, Wadleigh, Martha, Agrawal, Vaibhav, Aljurf, Mahmoud, Angel Diaz, Miguel, Avalos, Belinda R., Bacher, Ulrike, Bashey, Asad, Beitinjaneh, Amer M., Cerny, Jan, Chhabra, Saurabh, Copelan, Edward, Cutler, Corey S., DeFilipp, Zachariah, Gadalla, Shahinaz M., Ganguly, Siddhartha, Grunwald, Michael R., Hashmi, Shahrukh K., Kharfan-Dabaja, Mohamed A., Kindwall-Keller, Tamila, Kröger, Nicolaus, Lazarus, Hillard M., Liesveld, Jane L., Litzow, Mark R., Marks, David I., Nathan, Sunita, Nishihori, Taiga, Olsson, Richard F., Pawarode, Attaphol, Rowe, Jacob M., Savani, Bipin N., Savoie, Mary Lynn, Seo, Sachiko, Solh, Melhem, Tamari, Roni, Verdonck, Leo F., Yared, Jean A., Alyea, Edwin, Popat, Uday, Sobecks, Ronald, Scott, Bart L., Nakamura, Ryotaro, Mesa, Ruben, and Saber, Wael

Published
2020
Full Text
View/download PDF

27. Ipilimumab for Patients with Relapse after Allogeneic Transplantation

Author

Davids, Matthew S, Kim, Haesook T, Bachireddy, Pavan, Costello, Caitlin, Liguori, Rebecca, Savell, Alexandra, Lukez, Alexander P, Avigan, David, Chen, Yi-Bin, McSweeney, Peter, LeBoeuf, Nicole R, Rooney, Michael S, Bowden, Michaela, Zhou, Chensheng W, Granter, Scott R, Hornick, Jason L, Rodig, Scott J, Hirakawa, Masahiro, Severgnini, Mariano, Hodi, F Stephen, Wu, Catherine J, Ho, Vincent T, Cutler, Corey, Koreth, John, Alyea, Edwin P, Antin, Joseph H, Armand, Philippe, Streicher, Howard, Ball, Edward D, Ritz, Jerome, Bashey, Asad, and Soiffer, Robert J

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Clinical Research, Hematology, Regenerative Medicine, Pediatric, Patient Safety, Stem Cell Research - Nonembryonic - Non-Human, Cancer, Rare Diseases, Pediatric Cancer, Clinical Trials and Supportive Activities, Stem Cell Research, Transplantation, Stem Cell Research - Nonembryonic - Human, 6.2 Cellular and gene therapies, 5.2 Cellular and gene therapies, 6.1 Pharmaceuticals, Development of treatments and therapeutic interventions, Evaluation of treatments and therapeutic interventions, Adult, Aged, Antibodies, Monoclonal, CD4 Lymphocyte Count, Female, Hematologic Neoplasms, Hematopoietic Stem Cell Transplantation, Humans, Induction Chemotherapy, Ipilimumab, Leukemia, Lymphoma, Male, Middle Aged, Myeloproliferative Disorders, Recurrence, T-Lymphocytes, Regulatory, Transplantation Immunology, Transplantation, Homologous, Leukemia and Lymphoma Society Blood Cancer Research Partnership, Medical and Health Sciences, General & Internal Medicine, Biomedical and clinical sciences, Health sciences
Abstract

BackgroundLoss of donor-mediated immune antitumor activity after allogeneic hematopoietic stem-cell transplantation (HSCT) permits relapse of hematologic cancers. We hypothesized that immune checkpoint blockade established by targeting cytotoxic T-lymphocyte-associated protein 4 with ipilimumab could restore antitumor reactivity through a graft-versus-tumor effect.MethodsWe conducted a phase 1/1b multicenter, investigator-initiated study to determine the safety and efficacy of ipilimumab in patients with relapsed hematologic cancer after allogeneic HSCT. Patients received induction therapy with ipilimumab at a dose of 3 or 10 mg per kilogram of body weight every 3 weeks for a total of 4 doses, with additional doses every 12 weeks for up to 60 weeks in patients who had a clinical benefit.ResultsA total of 28 patients were enrolled. Immune-related adverse events, including one death, were observed in 6 patients (21%), and graft-versus-host disease (GVHD) that precluded further administration of ipilimumab was observed in 4 patients (14%). No responses that met formal response criteria occurred in patients who received a dose of 3 mg per kilogram. Among 22 patients who received a dose of 10 mg per kilogram, 5 (23%) had a complete response, 2 (9%) had a partial response, and 6 (27%) had decreased tumor burden. Complete responses occurred in 4 patients with extramedullary acute myeloid leukemia and 1 patient with the myelodysplastic syndrome developing into acute myeloid leukemia. Four patients had a durable response for more than 1 year. Responses were associated with in situ infiltration of cytotoxic CD8+ T cells, decreased activation of regulatory T cells, and expansion of subpopulations of effector T cells in the blood.ConclusionsOur early-phase data showed that administration of ipilimumab was feasible in patients with recurrent hematologic cancers after allogeneic HSCT, although immune-mediated toxic effects and GVHD occurred. Durable responses were observed in association with several histologic subtypes of these cancers, including extramedullary acute myeloid leukemia. (Funded by the National Institutes of Health and others; ClinicalTrials.gov number, NCT01822509.).

Published
2016

31. Hematopoietic stem cell mobilization for allogeneic stem cell transplantation by motixafortide, a novel CXCR4 inhibitor

Author

Crees, Zachary D., primary, Rettig, Michael P., additional, Bashey, Asad, additional, Devine, Steven M., additional, Jaglowski, Samantha, additional, Wan, Fei, additional, Zhou, Amy, additional, Harding, Melinda, additional, Vainstein-Haras, Abi, additional, Sorani, Ella, additional, Gliko-Kabir, Irit, additional, Grossman, Brenda J., additional, Westervelt, Peter, additional, DiPersio, John F., additional, and Uy, Geoffrey L., additional

Published
2023
Full Text
View/download PDF

36. Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation

Author

Sidana, Surbhi, Kumar, Shaji, Fraser, Raphael, Estrada-Merly, Noel, Giralt, Sergio, Agrawal, Vaibhav, Anderson, Larry D., Jr., Aljurf, Mahmoud, Banerjee, Rahul, Bashey, Asad, Battiwalla, Minoo, Beitinjaneh, Amer, Chakraborty, Rajshekhar, Chhabra, Saurabh, Dhakal, Binod, Dholaria, Bhagirathbhai, Hashmi, Shahrukh, Janakiram, Murali, Lee, Cindy, Lekakis, Lazaros, Murthy, Hemant S., Parrondo, Ricardo, Wangjam, Tamna, Usmani, Saad, Shah, Nina, Qazilbash, Muzaffar, and D'Souza, Anita

Published
2022
Full Text
View/download PDF

38. Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings

Author

Garcia, Jacqueline S., primary, Flamand, Yael, additional, Penter, Livius, additional, Keng, Michael, additional, Tomlinson, Benjamin K., additional, Mendez, Lourdes M., additional, Koller, Paul, additional, Cullen, Nicole, additional, Arihara, Yohei, additional, Pfaff, Kathleen, additional, Wolff, Jacquelyn O., additional, Brunner, Andrew M., additional, Galinsky, Ilene, additional, Bashey, Asad, additional, Antin, Joseph H., additional, Cutler, Corey, additional, Ho, Vincent, additional, Jonas, Brian A., additional, Luskin, Marlise R., additional, Wadleigh, Martha, additional, Winer, Eric S., additional, Savell, Alexandra, additional, Leonard, Rebecca, additional, Robertson, Taylor, additional, Davids, Matthew S., additional, Streicher, Howard, additional, Rodig, Scott J., additional, Ritz, Jerome, additional, Wu, Catherine J., additional, DeAngelo, Daniel J., additional, Neuberg, Donna, additional, Stone, Richard M., additional, and Soiffer, Robert J., additional

Published
2023
Full Text
View/download PDF

39. PD-1 blockade for relapsed lymphoma post–allogeneic hematopoietic cell transplant: high response rate but frequent GVHD

Author

Haverkos, Bradley M., Abbott, Diana, Hamadani, Mehdi, Armand, Philippe, Flowers, Mary E., Merryman, Reid, Kamdar, Manali, Kanate, Abraham Sebastian, Saad, Ayman, Mehta, Amitkumar, Ganguly, Siddhartha, Fenske, Timothy S., Hari, Parameswaran, Lowsky, Robert, Andritsos, Leslie, Jagasia, Madan, Bashey, Asad, Brown, Stacey, Bachanova, Veronika, Stephens, Deborah, Mineishi, Shin, Nakamura, Ryotaro, Chen, Yi-Bin, Blazar, Bruce R., Gutman, Jonathan, and Devine, Steven M.

Published
2017
Full Text
View/download PDF

40. Allogeneic Hematopoietic Cell Transplantation for Adult T Cell Acute Lymphoblastic Leukemia

Author

Hamilton, Betty Ky, Rybicki, Lisa, Abounader, Donna, Adekola, Kehinde, Advani, Anjali, Aldoss, Ibrahim, Bachanova, Veronika, Bashey, Asad, Brown, Stacey, DeLima, Marcos, Devine, Steven, Flowers, Christopher R., Ganguly, Siddharth, Jagasia, Madan, Kennedy, Vanessa E., Kim, Dennis Dong Hwan, McGuirk, Joseph, Pullarkat, Vinod, Romee, Rizwan, Sandhu, Karamjeet, Smith, Melody, Ueda, Masumi, Viswabandya, Auro, Vu, Khoan, Wall, Sarah, Zeichner, Simon B., Perales, Miguel-Angel, and Majhail, Navneet S.

Published
2017
Full Text
View/download PDF

42. Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes

Author

Oran, Betül, Ahn, Kwang Woo, Fretham, Caitrin, Beitinjaneh, Amer, Bashey, Asad, Pawarode, Attaphol, Wirk, Baldeep, Scott, Bart L., Savani, Bipin N., Bredeson, Christopher, Weisdorf, Daniel, Marks, David I., Rizzieri, David, Copelan, Edward, Hildebrandt, Gerhard C., Hale, Gregory A., Murthy, Hemant S., Lazarus, Hillard M., Cerny, Jan, Liesveld, Jane L., Yared, Jean A., Yves-Cahn, Jean, Szer, Jeffrey, Verdonck, Leo F., Aljurf, Mahmoud, van der Poel, Marjolein, Litzow, Mark, Kalaycio, Matt, Grunwald, Michael R., Diaz, Miguel Angel, Sabloff, Mitchell, Kharfan-Dabaja, Mohamed A., Majhail, Navneet S., Farhadfar, Nosha, Reshef, Ran, Olsson, Richard F., Gale, Robert Peter, Nakamura, Ryotaro, Seo, Sachiko, Chhabra, Saurabh, Hashmi, Shahrukh, Farhan, Shatha, Ganguly, Siddhartha, Nathan, Sunita, Nishihori, Taiga, Jain, Tania, Agrawal, Vaibhav, Bacher, Ulrike, Popat, Uday, and Saber, Wael

Published
2021
Full Text
View/download PDF

43. Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma

Author

Cornell, Robert F., D'Souza, Anita, Kassim, Adetola A., Costa, Luciano J., Innis-Shelton, Racquel D., Zhang, Mei-Jie, Huang, Jiaxing, Abidi, Muneer, Aiello, Jack, Akpek, Gorgun, Bashey, Asad, Bashir, Qaiser, Cerny, Jan, Comenzo, Raymond, Diaz, Miguel Angel, Freytes, César, Gale, Robert Peter, Ganguly, Siddhartha, Hamadani, Mehdi, Hashmi, Shahrukh, Holmberg, Leona, Hossain, Nasheed, Kamble, Rammurti T., Kharfan-Dabaja, Mohamed, Kindwall-Keller, Tamila, Kyle, Robert, Kumar, Shaji, Lazarus, Hillard, Lee, Cindy, Maiolino, Angelo, Marks, David I., Meehan, Kenneth, Mikhael, Joe, Nath, Rajneesh, Nishihori, Taiga, Olsson, Richard F., Ramanathan, Muthalagu, Saad, Ayman, Seo, Sachiko, Usmani, Saad, Vesole, David, Vij, Ravi, Vogl, Dan, Wirk, Baldeep M., Yared, Jean, Krishnan, Amrita, Mark, Tomer, Nieto, Yago, and Hari, Parameswaran

Published
2017
Full Text
View/download PDF

45. Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes—Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial

Author

Scott, Bart L., Pasquini, Marcelo C., Fei, Mingwei, Fraser, Raphael, Wu, Juan, Devine, Steve M., Porter, David L., Maziarz, Richard T., Warlick, Erica, Fernandez, Hugo F., Soiffer, Robert J., Alyea, Edwin, Hamadani, Mehdi, Bashey, Asad, Giralt, Sergio, Geller, Nancy L., Leifer, Eric, Hourigan, Christopher S., Gui, Gege, Mendizabal, Adam, Horowitz, Mary M., Deeg, H. Joachim, and Horwitz, Mitchell E.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results